Wang Yuan, Wang Yan, Jia Xiaoxia, Wang Zongwei, Li Xin, Mu Lin, Zhang Baoyu
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China.
Clin Rheumatol. 2021 Apr;40(4):1525-1531. doi: 10.1007/s10067-020-05374-z. Epub 2020 Sep 1.
We sought to determine whether high-density lipoprotein (HDL) function was altered in gout patients.
The study included 95 gout patients and 68 healthy controls. The concentrations of interleukin (IL)-1β and IL-9 were measured by ELISA, and indicators such as blood uric acid, liver and kidney function, blood glucose, and blood lipids were detected. To test for the anti-inflammatory and reverse cholesterol transport (RCT) function of HDL, 11 gout patients and 11 healthy controls were randomly selected for the BioVision cholesterol efflux test, which detects the RCT activity of HDL. To assess the anti-inflammatory function of HDL, cells in co-culture with HDL were treated with inflammatory stimuli such as tumor necrosis factor-α (TNF-α), and then, the cells were assayed for the expression of intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecule-1 (VCAM-1).
In total, this study enrolled 163 participants, including 95 non-hyperlipidemic gout patients and 68 healthy controls. IL-1β and IL-9 levels were significantly higher in the gout group than in the control group (85.26 ± 23.16 vs. 41.47 ± 6.48 and 33.77 ± 12.68 vs. 23.66 ± 4.53, respectively, P < 0.001). Additionally, plasma IL-1β and IL-9 levels were increased along with those of blood uric acid (R = 0.4116 and R = 0.4150, respectively, P < 0.001). Compared with the healthy controls, gout patients showed no differences in plasma apoA-1 levels or in the cholesterol efflux assay. Gout patients had increased ICAM-1 expression compared with the healthy controls (88.79 ± 3.68 vs. 86.27 ± 4.64, P < 0.05), but no difference in VCAM-1 expression was found (0.87 ± 0.43 vs. 0.98 ± 0.96, P > 0.05). In this assay, higher values indicate less suppression of ICAM-1 induction, which correlates with a reduced anti-inflammatory capacity.
The anti-inflammatory activities of HDLs are impaired in gout patients. Key Points • Gout patients show chronic inflammation. • The anti-inflammatory activity of high-density lipoprotein is impaired in gout patients.
我们试图确定痛风患者的高密度脂蛋白（HDL）功能是否发生改变。
该研究纳入了95例痛风患者和68例健康对照者。通过酶联免疫吸附测定法（ELISA）检测白细胞介素（IL）-1β和IL-9的浓度，并检测血尿酸、肝肾功能、血糖和血脂等指标。为了检测HDL的抗炎和逆向胆固醇转运（RCT）功能，随机选择11例痛风患者和11例健康对照者进行BioVision胆固醇流出试验，该试验可检测HDL的RCT活性。为了评估HDL的抗炎功能，将与HDL共培养的细胞用肿瘤坏死因子-α（TNF-α）等炎性刺激物处理，然后检测细胞间黏附分子（ICAM）和血管细胞黏附分子-1（VCAM-1）的表达。
本研究共纳入163名参与者，包括95例非高脂血症痛风患者和68例健康对照者。痛风组的IL-1β和IL-9水平显著高于对照组（分别为85.26±23.16对41.47±6.48以及33.77±12.68对23.66±4.53，P<0.001）。此外，血浆IL-1β和IL-9水平随血尿酸水平升高而升高（分别为R=0.4116和R=0.4150，P<0.001）。与健康对照者相比，痛风患者的血浆载脂蛋白A-1水平或胆固醇流出试验无差异。与健康对照者相比，痛风患者的ICAM-1表达增加（88.79±3.68对86.27±4.64，P<0.05），但VCAM-1表达无差异（0.87±。43对0.98±0.96，P>0.05）。在该试验中，较高的值表明对ICAM-1诱导的抑制作用较小，这与抗炎能力降低相关。
痛风患者HDL的抗炎活性受损。要点•痛风患者表现为慢性炎症。•痛风患者高密度脂蛋白的抗炎活性受损。
Zotero 插件